rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461.

CX-5461 DNA damage response RNA polymerase I ovarian cancer rDNA copy number

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2020
Historique:
received: 16 12 2019
accepted: 15 06 2020
entrez: 29 7 2020
pubmed: 29 7 2020
medline: 29 7 2020
Statut: epublish

Résumé

Hyperactivation of RNA polymerase I (Pol I) transcription of ribosomal RNA (rRNA) genes (rDNA) is a key determinant of growth and proliferation and a consistent feature of cancer cells. We have demonstrated that inhibition of rDNA transcription by the Pol I transcription inhibitor CX-5461 selectively kills tumor cells

Identifiants

pubmed: 32719798
doi: 10.3389/fcell.2020.00568
pmc: PMC7349920
doi:

Types de publication

Journal Article

Langues

eng

Pagination

568

Informations de copyright

Copyright © 2020 Son, Hannan, Poortinga, Hein, Cameron, Ganley, Sheppard, Pearson, Hannan and Sanij.

Références

Nat Commun. 2013;4:1598
pubmed: 23511463
PLoS Genet. 2017 Sep 7;13(9):e1006994
pubmed: 28880866
PLoS One. 2014 May 30;9(5):e98586
pubmed: 24879416
EMBO J. 2004 Aug 18;23(16):3325-35
pubmed: 15282543
Nat Commun. 2019 May 8;10(1):2110
pubmed: 31068593
Cell Mol Life Sci. 2007 Jan;64(1):29-49
pubmed: 17171232
Cell Biosci. 2014 Aug 19;4:43
pubmed: 25949792
Nucleic Acids Res. 2011 Jul;39(12):4949-60
pubmed: 21355038
Oncotarget. 2016 Aug 2;7(31):49800-49818
pubmed: 27391441
Trends Mol Med. 2013 Nov;19(11):643-54
pubmed: 23953479
Annu Rev Cell Dev Biol. 2008;24:131-57
pubmed: 18616426
Biochim Biophys Acta. 2013 Mar-Apr;1829(3-4):393-404
pubmed: 23063748
PLoS One. 2016 Jun 14;11(6):e0157276
pubmed: 27299313
Int J Mol Sci. 2017 Jan 20;18(1):
pubmed: 28117679
EMBO J. 2010 Jul 7;29(13):2135-46
pubmed: 20168299
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4737-4742
pubmed: 29669917
Genome Res. 2015 Feb;25(2):201-12
pubmed: 25452314
Nat Commun. 2020 May 26;11(1):2641
pubmed: 32457376
Sci Signal. 2011 Aug 30;4(188):ra56
pubmed: 21878679
Epigenetics. 2009 Aug 16;4(6):374-82
pubmed: 19717978
Nat Rev Cancer. 2018 Jan;18(1):51-63
pubmed: 29192214
Mol Cell. 2001 Nov;8(5):1063-73
pubmed: 11741541
Trends Biotechnol. 2013 Jul;31(7):397-405
pubmed: 23664777
Cell Stem Cell. 2014 Dec 4;15(6):720-34
pubmed: 25479748
Proc Natl Acad Sci U S A. 2012 May 22;109(21):8161-6
pubmed: 22570494
Commun Biol. 2019 Jan 28;2:39
pubmed: 30701204
Gene. 2017 May 15;612:36-48
pubmed: 27989772
Cancer Cell. 2012 Jul 10;22(1):51-65
pubmed: 22789538
Expert Opin Ther Targets. 2013 Aug;17(8):873-8
pubmed: 23862680
Biochim Biophys Acta. 2013 Mar-Apr;1829(3-4):405-17
pubmed: 23291532
J Cell Biol. 2008 Dec 29;183(7):1259-74
pubmed: 19103806
Biochim Biophys Acta. 2013 Mar-Apr;1829(3-4):342-60
pubmed: 23153826
PLoS Genet. 2017 Jul 17;13(7):e1006899
pubmed: 28715449
Cancer Cell. 2014 Jan 13;25(1):77-90
pubmed: 24434211
Cancer Discov. 2019 Aug;9(8):1036-1049
pubmed: 31092402
Cell. 1989 Jun 2;57(5):753-61
pubmed: 2720786
FEBS Lett. 2017 Jul;591(13):1892-1901
pubmed: 28580607
Cell. 2002 May 31;109(5):545-8
pubmed: 12062097
Gene. 2012 Feb 10;493(2):176-84
pubmed: 21893173
Blood. 2017 May 25;129(21):2882-2895
pubmed: 28283481
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4053-4060
pubmed: 32041867
Annu Rev Pharmacol Toxicol. 2010;50:131-56
pubmed: 20055700
Cancer Discov. 2016 Jan;6(1):59-70
pubmed: 26490423
Chromosome Res. 2019 Mar;27(1-2):73-87
pubmed: 30604343
PLoS Genet. 2017 Jun 22;13(6):e1006771
pubmed: 28640831
Nat Commun. 2017 Feb 17;8:14432
pubmed: 28211448
Oncogene. 2015 Jan 22;34(4):403-12
pubmed: 24608428
Science. 2010 Feb 5;327(5966):693-6
pubmed: 20133573
Mol Cell Biol. 2003 Mar;23(5):1558-68
pubmed: 12588976
Chromosome Res. 2019 Mar;27(1-2):31-40
pubmed: 30617621
PLoS Genet. 2014 Aug 14;10(8):e1004505
pubmed: 25121932
Trends Biochem Sci. 1999 Nov;24(11):437-40
pubmed: 10542411
Genome Res. 2005 Aug;15(8):1079-85
pubmed: 16024823
Chromosome Res. 2019 Mar;27(1-2):109-127
pubmed: 30656516
Subcell Biochem. 2013;61:211-36
pubmed: 23150253
Chromosome Res. 2019 Mar;27(1-2):57-72
pubmed: 30556094
EMBO J. 2005 Jan 12;24(1):120-7
pubmed: 15577942
Hum Mol Genet. 2009 Sep 15;18(18):3417-28
pubmed: 19542097
Clin Cancer Res. 2016 Nov 15;22(22):5539-5552
pubmed: 27486174
Epigenetics. 2020 Jan - Feb;15(1-2):85-106
pubmed: 31352858
Cell Rep. 2016 Mar 1;14(8):1876-82
pubmed: 26904956
Cancer Res. 2009 Dec 1;69(23):9096-104
pubmed: 19920195

Auteurs

Jinbae Son (J)

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.

Katherine M Hannan (KM)

ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.
Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, VIC, Australia.

Gretchen Poortinga (G)

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Department of Medicine, St. Vincent's Hospital, The University of Melbourne, Parkville, VIC, Australia.

Nadine Hein (N)

ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.

Donald P Cameron (DP)

ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.

Austen R D Ganley (ARD)

School of Biological Sciences, The University of Auckland, Auckland, New Zealand.

Karen E Sheppard (KE)

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, VIC, Australia.

Richard B Pearson (RB)

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, VIC, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.

Ross D Hannan (RD)

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.
Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, VIC, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.
School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia.

Elaine Sanij (E)

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, Australia.

Classifications MeSH